Machine Learning in Drug Discovery: A Comprehensive Analysis of Applications, Challenges, and Future Directions

Arjun Reddy  Kunduru

Arjun Reddy Kunduru Independent Researcher, Orlando, FL, USA

Keywords: Machine Learning, Drug Discovery, Cloud Computing, Advance Applications

Abstract

Machine learning has revolutionized drug discovery by speeding up the process and improving therapeutic interventions, transforming the pharmaceutical research and development landscape.

The paper embarks on a meticulous journey, delving into the intricate fabric of machine learning's integration into drug discovery. It deftly navigates through the virtual corridors of compound screening and virtual screening, where machine learning algorithms intricately assess massive chemical libraries, substantially hastening the identification of potential drug candidates. The analysis extends to encompass quantitative structure-activity relationship (QSAR) modeling, predictive ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) modeling, de novo drug design, and target identification and validation, meticulously unraveling the pivotal role machine learning plays in each facet.

Yet this transformative union does not come without its share of challenges. The paper uncovers the nuances of data quality and quantity, grapples with the intricacies of interpretability, and addresses the critical need to harmonize domain knowledge with data-driven methodologies. It illuminates the hurdles of transferability and generalization, coupled with the ethical and regulatory considerations that loom large over this cutting-edge convergence.

Furthermore, this paper casts an anticipatory glance toward the future horizons of this symbiotic relationship between machine learning and drug discovery. It envisions a time when there will be explainable AI, multi-modal data integration, reinforcement learning for compound optimization, collaborative AI platforms, and strong ethical and regulatory frameworks. By synthesizing insights gleaned from a systematic review of existing literature, this paper aims to spotlight the profound metamorphosis that machine learning has ushered into the realm of drug discovery, underscoring its pivotal role in revolutionizing, and reshaping the contours of pharmaceutical research.

References

Aliper, A., Plis, S., Artemov, A., Ulloa, A., Mamoshina, P., & Zhavoronkov, A. (2016). Deep learning applications for predicting the pharmacological properties of drugs and drug repurposing using transcriptomic data Molecular Pharmaceutics, 13(7), 2524–2530.

Ma, J., Sheridan, R. P., Liaw, A., Dahl, G. E., & Svetnik, V. (2015). Deep neural networks as a method for quantitative structure-activity relationships Journal of Chemical Information and Modeling, 55(2), 263–274.

Cherkasov, A., Muratov, E. N., Fourches, D., Varnek, A., Baskin, I. I., Cronin, M., ... & Tropsha, A. (2014). QSAR modeling: Where have you been? Where are you going? Journal of Medicinal Chemistry, 57(12), 4977–5010.

Xu, Y., Dai, Z., Chen, F., & Gao, S. (2019). Exploring convolutional neural networks for multi-target ADMET prediction Journal of Cheminformatics, 11(1), 16.

Gómez-Bombarelli, R., Wei, J. N., Duvenaud, D., Hernández-Lobato, J. M., Sánchez-Lengeling, B., Sheberla, D., ... & Aspuru-Guzik, A. (2018). Automatic chemical design using a data-driven continuous representation of molecules ACS Central Science, 4(2), 268–276.

Yamanishi, Y., Araki, M., Gutteridge, A., Honda, W., & Kanehisa, M. (2008). Prediction of drug-target interaction networks from the integration of chemical and genomic spaces Bioinformatics, 24(13), i232–i240.

Vilar, S., & Chakrabarti, M. (2019). cost- and time-effective drug-drug interaction predictions by ensembling multiple multi-label learning algorithms. Scientific Reports, 9(1), 1–13.

Duvenaud, D. K., Maclaurin, D., Aguilera-Iparraguirre, J., Gómez-Bombarelli, R., Hirzel, T., Aspuru-Guzik, A., & Adams, R. P. (2015). Convolutional networks on graphs for learning molecular fingerprints In Advances in neural information processing systems (pp. 2224–2232).

Zhang, L., Tan, J., Han, D., Zhu, H., Fromm, M., & Chen, Y. (2015). Data mining of a high-throughput screening database reveals duloxetine as a therapeutic agent for neurodegenerative diseases. ACS Chemical Neuroscience, 6(11), 1890–1898.

Hughes, T. B., Miller, G. P., Swamidass, S. J., & Fotouhi, F. (2010). A dataset to evaluate structure-based virtual screening. Journal of Cheminformatics, 2(1), 1–10.

Oskooei, A., & Shahabi, H. (2019). DeepChem: A genome-scale chemoinformatics library arXiv preprint arXiv:1903.08528.

Vanhaelen, Q., Mamoshina, P., Aliper, A. M., Artemov, A., Lezhnina, K., Ozerov, I., ... & Zhavoronkov, A. (2017). Design of efficient computational workflows for in silico drug repurposing Drug Discovery Today, 22(2), 210–222.